Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence

Annals of the New York Academy of Sciences

Volumn 965, Issue , 2002, Pages 92-108

  Baumann, Michael H ^a   Phillips, Jennifer M ^a   Ayestas, Mario A ^a   Ali, Syed F ^b   Rice, Kenner C ^c   Rothman, Richard B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Cocaine; DA transporter; Drug addiction; GBR decanoate; GBR12909; Methamphetamine; Pharmacotherapies; Psychomotor stimulants

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; METHAMPHETAMINE; PROLACTIN; QUINPIROLE; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTORADIOGRAPHY; BRAIN REGION; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG EFFECT; LIMBIC CORTEX; LOCOMOTION; MALE; MICRODIALYSIS; NERVE ENDING; NONHUMAN; NUCLEUS ACCUMBENS; PROLACTIN BLOOD LEVEL; RAT; SYNAPSE;

ANIMALIA;

EID: 0036296960     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04154.x     Document Type: Conference Paper

References (70)

1. Increasing morbidity and mortality associated with abuse of methamphetamine - United States, 1991-1994
2. Methamphetamine and the expanding complications of amphetamines
3. Will the methamphetamine problem go away?
4. Overview of potential treatment medications for cocaine dependence
5. Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects
6. Neurobiology of addiction
7. Neurochemistry of amphetamine
8. Mechanisms of biogenic amine neurotransmitter transporters
9. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse
10. High affinity dopamine uptake inhibitors as potential cocaine antagonists
11. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat
12. A review of the effects of dopaminergic agents on humans, animals, and drug seeking behavior, and its implications for medication development: Focus on GBR12909
13. The dopamine inhibitor GBR12909: Selectivity and molecular mechanism of action
14. Identification of a GBR12935 homolog, LR111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters
15. 125I]RTI-55
16. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine
17. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping
18. Dopamine transporter ligand binding domains
19. 3H]WIN35428 binding to dopamine uptake sites in vivo more rapidly than mazindol and GBR12909
20. 11C]raclopride continuous infusion PET scans
21. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats
22. Effects of dopamine reuptake inhibitors on food and cocaine maintained responding. II: Comparisons with other drugs and repeated administrations
23. Differential reinforcing effects of cocaine and GBR-12909: Biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system
24. Effects of drug history on the acquisition of responding maintained by GBR12909 in rhesus monkeys
25. Vanoxerine, National Institute on Drug Abuse
26. Drug abuse treatment entry and engagement: Report of a meeting on treatment readiness
27. Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909
28. Oxygenated analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl] 4-(3-phenylpropyl)piperazines (GBR12935 and GBR12909) as potential extended-action cocaine-abuse therapeutic agents
29. 14c-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs
30. Prolongation of the action of intramuscular formulations of phenothiazines
31. 125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate
32. 125I]RTI-55: In vitro binding and autoradiographic characterization
33. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications
34. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors
35. Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens
36. Differential neuroendocrine responsiveness to morphine in Lewis, Fischer 344, and ACI inbred rats
37. Chronic administration of the selective dopamine uptake inhibitor, GBR12909, but not cocaine, produces marked decreases in dopamine transporter density
38. Regulated trafficking of the human dopamine transporter
39. Membrane trafficking regulates the activity of the human dopamine transporter
40. Amphetamine: Effects on catecholamine systems and behavior
41. Neurochemical changes in cocaine withdrawal
42. Striatal dopamine nerve terminal markers in human chronic methamphetamine users
43. 11C]WIN-35,428 positron emission tomograpgy studies and direct in vitro determinations
44. Cocaine addiction: Psychology and neurophysiology
45. Psychiatric comorbidity of methamphetamine dependence in a forensic sample
46. From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters
47. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: Amphetamine specificity for inhibition and efflux
48. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to stereoisomers of amphetamine and methamphetamine
49. Pharmacokinetic and pharmacodynamic analysis of the action of amphetamine and D-methamphetamine on dopamine terminals
50. Methamphetamine dependence: Medication development efforts based on a dual deficit model of stimulant addiction
51. Effects of GBR12909 on responding maintained under a progressive-ratio schedule of methamphetamine delivery in rhesus monkeys
52. Correlates of outpaient drug-treatment drop-out among methamphetamine users
53. Dose response of prophylactic antipsychotics
54. Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: Involvement of serotonin 1A receptors
55. Reinforcing effects of certain serotonin-releasing amphetamine derivatives
56. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers
57. Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: Concordance with clinical studies
58. Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat
59. Discriminative stimulus properties of cocaine: Enhancement by monoamine reuptake inhibitors
60. Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic D-amphetamine treatment
61. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: Repeated administration
62. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: Comparison with quinpirole and apomorphine
63. Do autoreceptors mediate dopamine agonist-induced yawning and suppression of exploration? A critical review
64. Dopamine as a prolactin (PRL) inhibitor
65. 3 receptor agonists, 7-OH-DPAT and quinpirole, on prolactin secretion in rats
66. In vivo human dopamine transporter occupancy of a potential cocaine treatment agent
67. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects